

(12) STANDARD PATENT

(11) Application No. AU 2004255466 B2

(19) AUSTRALIAN PATENT OFFICE

(54) Title
Pharmaceutical formulation comprising levothyroxine sodium

(51) International Patent Classification(s)
A61K 9/20 (2006.01) **A61K 31/198** (2006.01)

(21) Application No: **2004255466** (22) Date of Filing: **2004.07.08**

(87) WIPO No: **WO05/004849**

(30) Priority Data

(31) Number
0316206.2 (32) Date
2003.07.10 (33) Country
GB

(43) Publication Date: **2005.01.20**
(44) Accepted Journal Date: **2007.07.26**

(71) Applicant(s)
Glaxo Group Limited

(72) Inventor(s)
Roman, Wanda;Strozyk, Małgorzata Anna;Krohn, Heiner;Schlehahn, Hendrik;Konieczna, Małgorzata

(74) Agent / Attorney
Davies Collison Cave, GPO Box 4387, Melbourne, VIC, 3001

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
20 January 2005 (20.01.2005)

PCT

(10) International Publication Number
WO 2005/004849 A3

(51) International Patent Classification⁷: **A61K 9/20**

(21) International Application Number: PCT/EP2004/007667

(22) International Filing Date: 8 July 2004 (08.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 0316206.2 10 July 2003 (10.07.2003) GB

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KONIECZNA, Małgorzata** [PL/PL]; GlaxoSmithKline Pharmaceuticals, Ul. Grunwaldzka 189, PL-60-322 Poznań (PL). **KROHN, Heiner** [DE/DE]; GlaxoSmithKline GmbH & Co. KG, GlaxoSmithKline Group, Industriestrasse 32-36, 23843 Bad Oledesloe (DE). **ROMAN, Wanda** [PL/PL]; GlaxoSmithKline Pharmaceuticals, Ul. Grunwaldzka 189, PL-60-322 Poznań (PL). **SCHLEHAHN, Hendrik** [DE/DE]; GlaxoSmithKline GmbH & Co. KG, GlaxoSmithKline Group, Industriestrasse 32-36, 23843 Bad Oledesloe (DE). **STROZYK, Małgorzata, Anna** [PL/PL]; GlaxoSmithKline Pharmaceuticals, Ul. Grunwaldzka 189, PL-60-322 Poznań (PL).

(74) Agent: **BAKER, Suzanne, Jane**; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CII, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HU, IE, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

(88) Date of publication of the international search report: 6 May 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL FORMULATION COMPRISING LEVOTHYROXINE SODIUM

(57) **Abstract:** There is provided a stable pharmaceutical formulation comprising (a) an effective amount of levothyroxine sodium, (b) microcrystalline cellulose which has a mean particle size of less than 125µm and is present in an amount of 60 to 85% w/w based upon the total weight of the formulation, and (c) pregelatinised starch present in an amount of 5 to 30% w/w based upon total weight of the formulation. There is also provided a process for the preparation of such a formulation.

WO 2005/004849 A3

PHARMACEUTICAL FORMULATION

The present invention relates to stable pharmaceutical formulations of levothyroxine sodium, useful in the treatment of thyroid hormone disorders in mammals, including 5 humans. The invention also relates to a process for preparing such a formulation.

Levothyroxine sodium is widely used in the treatment and/or prophylaxis of thyroid hormone disorders. Levothyroxine sodium is presently commercially available under the 10 trademark Eltroxin™ in the form of 50 μ g and 100 μ g tablets. These tablets contain levothyroxine sodium, lactose, magnesium stearate, acacia powder, sodium citrate and maize starch. Whilst levothyroxine sodium is relatively stable in pure form, pharmaceutical formulations containing levothyroxine sodium exhibit a relatively short shelf life, particularly under conditions of high light, heat, air and humidity (see "Kinetics 15 of Degradation of Levothyroxin Sodium in Aqueous solution and in Solid State", Chong Min Won, Pharmaceutical Research, Vol. 9, No 1, (1992), 131-137). The present invention is therefore directed at providing a stable solid dosage form of levothyroxine sodium. It is also desired that the solid dosage form disintegrates rapidly, thereby ensuring rapid release of the active ingredient, and is aesthetically acceptable and palatable to the patient.

20 The present inventors have found that a pharmaceutical formulation comprising levothyroxine sodium, microcrystalline cellulose with a mean particle size less than 125 μ m and pregelatinised starch provides a solid dosage form with improved stability and disintegration characteristics that is aesthetically acceptable and palatable to the patient. 25 Accordingly, the present invention provides a pharmaceutical formulation comprising (a) an effective amount of levothyroxine sodium, (b) microcrystalline cellulose which has a mean particle size of less than 125 μ m and is present in an amount of 60 to 85% w/w based upon the total weight of the formulation and (c) pregelatinised starch present in an amount of 5 to 30% w/w based upon total weight of the formulation. The pharmaceutical 30 formulations of the present invention have improved stability such that they are stable to the extent that potency decreases by less than 5%, preferably less than 4%, more preferably less than 3% when the pharmaceutical formulation is stored at 25°C and 60% relative humidity for 12 months. The pharmaceutical formulations of the present invention have improved disintegration characteristics such that they have a disintegration time of 35 less than 6 minutes, preferably less than 5 minutes, more preferably less than 4 minutes when tested in the disintegration test as described in the Examples section below.

40 The chemical name for levothyroxine sodium is sodium (S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propionate. Levothyroxine sodium is the monosodium salt of the levo-rotatory isomer of thyroxine. Levothyroxine sodium may exist as one or more polymorphic forms, for example one or more crystalline forms, amorphous forms, phases, solid solutions and/or mixtures thereof. All such forms of levothyroxine sodium and/or mixtures thereof are encompassed by the present invention. Preferably the

levothyroxine sodium for use in pharmaceutical formulations of the present invention is in hydrated form. More preferably, the levothyroxine sodium for use in pharmaceutical formulations of the present invention is in the pentahydrate form.

5 Preferably, the levothyroxine sodium is present in an amount less than 1% w/w based upon the total weight of the formulation, more preferably 0.01-0.30% w/w, even more preferably 0.03-0.25% w/w, most preferably 0.06-0.20% w/w. The minimum amount of levothyroxine sodium can vary, so long as an effective amount is utilised to cause the desired pharmacological effect.

10 Preferably, the microcrystalline cellulose has a mean particle size of $\leq 100\mu\text{m}$, more preferably $\leq 75\mu\text{m}$, even more preferably $\leq 50\mu\text{m}$. Preferably, the microcrystalline cellulose is selected from microcrystalline cellulose grade 101, 102, or 103, more preferably grade 101 or 102, most preferably grade 101. The term 'Grade 101' as used 15 herein means material with nominal mean particle size 50 μm and moisture content $\leq 5.0\%$ in accordance with the European Pharmacopeia (2002). The term 'Grade 102' as used herein means material with nominal mean particle size 100 μm and moisture content $\leq 5.0\%$ in accordance with the European Pharmacopeia (2002). The term 'Grade 103' as used herein means material with nominal mean particle size 50 μm and moisture content 20 $\leq 3.0\%$ in accordance with the European Pharmacopeia (2002). The term 'Grade 200' as used herein means material with nominal mean particle size 180 μm and moisture content $\leq 5.0\%$ in accordance with the European Pharmacopeia (2002). Preferably the microcrystalline cellulose is sourced from FMC Corporation, JRS Rettenmaier or Sähne (Germany) or Wei Ming (Taiwan), more preferably Wei Ming (Taiwan).

25 Preferably, the microcrystalline cellulose is present in an amount of 60 to 85% w/w based on the total weight of the formulation, more preferably 65 to 80% w/w, most preferably 70 to 80% w/w.

30 The term 'pregelatinised starch' as used herein means partially pregelatinised starch typically containing about 5% of free amylose, 15% of free amylopectin and 80% unmodified starch. It is produced by subjecting moistened starch to mechanical pressure in order to rupture some or all of the starch granules. The resultant material is ground and its moisture content adjusted such that it possesses good flow and compression 35 characteristics. Typical cold water solubility of partially pregelatinised starch, e.g. Starch 1500 (Colorcon) is 10-20%. Pregelatinised starch is further defined in the European Pharmacopeia (2002) which is included herein by reference. Preferably, the pregelatinised starch is present in an amount of 5 to 30% w/w based on the total weight of the formulation, more preferably 10 to 30% w/w, most preferably 15 to 25% w/w.

40 Preferably, the ratio of microcrystalline cellulose:pregelatinised starch is in the range of 2:1 to 15:1, more preferably 2.5:1 to 8:1, most preferably 3:1 to 5:1.

Preferably, the microcrystalline cellulose and pregelatinised starch contain water. Preferably, the water comprises 3-6% w/w based on the total weight of the formulation, more preferably about 4.5% (e.g. 4.5% - 5.0%).

5

Preferably, the pharmaceutical formulation includes one or more glidants/lubricants. Suitable glidants/lubricants for use in the present invention include colloidal silicon dioxide, talc, magnesium stearate, zinc stearate, calcium stearate, sodium stearate fumarate and sodium magnesium lauryl sulphate. Preferably, the glidants/lubricants are selected from one or more of: colloidal silicon dioxide, talc and magnesium stearate.

10

Preferably, the glidant/lubricant is present in an amount 1-10% of the total weight of the formulation, more preferably 2-9% of the total weight of the formulation, most preferably 3-8% of the total weight of the formulation.

15

Preferably, talc is present in an amount 1-5% of the total weight of the formulation, more preferably 2-4% of the total weight of the formulation, most preferably 2.5-3.5% of the total weight of the formulation.

20

Preferably, colloidal anhydrous silica is present in an amount 1-5% of the total weight of the formulation, more preferably 1-3% of the total weight of the formulation, most preferably 1.5-2.5% of the total weight of the formulation.

25

Preferably, magnesium stearate is present in an amount 0.1-5% of the total weight of the formulation, more preferably 0.5-4% of the total weight of the formulation, most preferably 0.8-1.5% of the total weight of the formulation.

30

Preferably, the pH of the pharmaceutical formulation is in the range pH 6.8 to 8.2, preferably pH 7.2 to 7.8 when suspended in water in a ratio water:pharmaceutical formulation of 10:1.

35

The formulations of the invention may, if desired, further include one or more pharmaceutically acceptable excipients. All such excipients must be "pharmaceutically acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Pharmaceutically acceptable excipients may include colours, flavours e.g. menthol, sweeteners e.g. mannitol, preservatives, stabilisers, antioxidants and any other excipients known to those skilled in the art.

40

It is to be understood that the present invention covers all combinations of particular and preferred groups described hereinabove.

The present invention provides a pharmaceutical formulation for use in medical therapy, e.g. in the treatment of thyroid hormone disorders in an animal, e.g. a mammal such as a human. Levothyroxine and other thyroid hormones are known to serve as hormone replacement therapy when the thyroid function has been reduced or is completely absent for a variety of disease states, including, hypothyroidism, myxedema, cretinism and 5 obesity, preferably hypothyroidism.

For each of the above-indicated utilities and indications the amount required of levothyroxine sodium will depend on a number of factors including the severity of the 10 condition to be treated and the identity of the recipient and will ultimately be at the discretion of the attendant physician or veterinarian. Typically, a physician will determine the actual dosage which will be most suitable for an individual subject. The specific dose level and frequency of dosage for any particular individual may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the 15 metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual undergoing therapy. In general, however, for each of these utilities and indications, a suitable effective dose will be in the range 1.0 to 6.0 μ g per kilogram bodyweight of recipient per day, preferably in the 1.5 to 20 5.0 μ g per kilogram bodyweight per day (unless otherwise indicated, all weights are calculated with respect to the free base active ingredient).

The desired dose is preferably presented as one, two, three or four sub-doses 25 administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing about 10 to 300 μ g, preferably 10-200 μ g, more preferably 25-150 μ g, of active ingredient per unit dose form, most preferably 50 μ g or 100 μ g of active ingredient per unit dose form.

For example, a 50 μ g tablet may comprise 0.0425-0.0575mg levothyroxine sodium, 50-30 60mg microcrystalline cellulose, 12-17mg pregelatinised starch, 2-3mg talc, 1-2mg colloidal anhydrous silica and 0.5-1mg magnesium stearate. A 100 μ g tablet may comprise 0.085-0.115mg levothyroxine sodium, 100-120mg microcrystalline cellulose, 24-34 pregelatinised starch, 4-6mg talc, 2-4mg colloidal anhydrous silica and 1-2mg magnesium stearate.

35 The pharmaceutical formulation is preferably administered orally and is preferably in the form of a tablet. However, in addition to tablets, the composition according to the present invention may also be administered in the form of capsules, caplets, gelcaps, pills, and any other oral dosage forms known in the pharmaceutical art.

The term "treatment" and derivatives such as "treating" as used herein includes both treatment and prophylaxis. Prophylaxis is relevant in relation to protection against such conditions such as hypothyroidism.

5 A further aspect of the invention provides a process for preparing a pharmaceutical formulation according to the invention.

10 The tablet may be prepared either by a wet granulation or by a direct compression process. Preferably a direct compression process is used, e.g. using a conventional high speed rotary press.

15 Preferably, the pharmaceutical formulation is prepared by making an initial preparation of a triturate of levothyroxine sodium and subsequently incorporating the triturate into the tablet formulation. A triturate of levothyroxine sodium comprises levothyroxine sodium and a suitable carrier, e.g. microcrystalline cellulose, wherein the levothyroxine sodium is present in a greater concentration in the triturate than in the final tablet formulation. Preferably, the triturate comprises 2-3% w/w levothyroxine sodium of total weight of triturate. Preparation using a triturate improves distribution of the low concentration of drug throughout the blend and uniformity in the tablets i.e. homogeneous incorporation.

20 20 Preferably, the process comprises the steps of: (a) preparing a triturate of levothyroxine sodium and microcrystalline cellulose, (b) mixing the triturate with the remaining components of the pharmaceutical formulation, and (c) compression.

25 25 Levothyroxine sodium can be obtained from the thyroid gland of domesticated animals, or alternatively the hormone can be prepared synthetically. Methods for making active ingredient are disclosed in Hagers Handbuch der pharmazeutischen Praxis, - 5., vollst. Neubearb., Bd.8. Stoffe: E-O / F... Von Bruchhausen; (Hrgs.). Bearb... von M. Albinus – 1993, Springer-Verlag Berlin Heidelberg 1993, pages 733 – 734; S. Rolski, Chemia 30 środków leczniczych, str. 654-655, PZWL, Warszawa 1968. The contents of which are incorporated herein by reference.

35 35 The formulation may be introduced into a container which is then closed. The container may be sealed, e.g. by LDPE tamper-evident snap fit closures. It may be a single-dose or multi-dose container. The container may be bottles, jars, bags or sachets. Sachets, especially foil sachets (foil-foil blisters), are particularly suitable for single dose packaging. Bottles, particularly high density polyethylene (HDPE) or polypropylene (PP) bottles are particularly suitable for multi-dose packaging.

40 40 The following examples illustrate aspects of this invention but should not be construed as limiting the scope of the invention in any way.

Examples**Example 1: Preparation of Levothyroxine Sodium Tablets**5 (a) **Formulation**

	[kg]
Levothyroxine sodium pentahydrate	0.074
Microcrystalline cellulose	75.0
Pregelatinised starch	20.0
10 Talc	3.0
Colloidal silicon dioxide	2.0
Magnesium stearate	1.0

Manufacturing Process

15 Levothyroxine sodium tablets were manufactured by a direct compression process comprising the following steps:

- preparation of a levothyroxine sodium triturate with a portion of the microcrystalline cellulose by simple blending
- blending the remainder of the microcrystalline cellulose and pregelatinised starch with the levothyroxine sodium triturate to produce a uniform content of active substance;
- addition of the talc, silicon dioxide colloidal and magnesium stearate, followed by blending to prepare a powder mixture;
- compression of levothyroxine sodium tablets at a crushing strength of not less than 3Kp and a resulting strength of 3.5 – 10Kp.

25

 (b) **Formulation**

	[kg]
Levothyroxine sodium pentahydrate	0.074
Microcrystalline cellulose	75.0
30 Pregelatinised starch	20.0
Talc	3.0
Colloidal silicon dioxide	2.0
Magnesium stearate	1.0

35 **Manufacturing Process** The manufacturing process for Example 1(b) differed from Example 1(a) in that a preblend of the remainder of microcrystalline cellulose and colloidal silicon dioxide was made before blending with the levothyroxine sodium triturate and pregelatinised starch.

40 **Example 2: Stability of Levothyroxine Sodium Tablets.**

Comparative stability studies of levothyroxine sodium tablets were based on testing of levothyroxine sodium and total impurities contents after storage of tablets at (i) 40°C/75%RH, (ii) 30°C/60%RH, and (iii) 25°C/60%RH. Suitable HPLC methods were applied. Stability was measured in terms of levothyroxine sodium content and total impurities content:

5 **Total impurities contents** were determined using the assay method for levothyroxine sodium tablets in the British Pharmacopoeia 2002 with a sample concentration of 50 μ g/ml, sample solvent: methanol and 0.02 M aqueous NaOH (1:1), an injection volume 10 of 100 μ l and a phase flow rate of 1.5ml/min.

10 **Levothyroxine sodium contents** were determined using the assay method for levothyroxine sodium tablets in the British Pharmacopoeia 2002 using a sample concentration of 50 μ g/ml, sample solvent: methanol and 0.02 M aqueous NaOH (1:1) and 15 phase flow rate of 1.5 ml/min.

The results of these stability tests are provided in tables (A) to (C).

Conclusions

20 (A) **Stability of Levothyroxine Sodium Tablets:** comparison of levothyroxine sodium tablets prepared according to Example 1(b) with EltroxinTM tablets.

25 The data shows that at 3-9 months after storage a higher levothyroxine sodium content is maintained in tablets according to Example 1(b) than in the marketed formulation of EltroxinTM and total impurities are lower in tablets according to Example 1(b) than in marketed formulation of EltroxinTM.

30 (B) **Stability of Levothyroxine Sodium Tablets:** effect of microcrystalline cellulose particle size.

35 The data shows that a higher levothyroxine sodium content is maintained and the total impurities are lower when microcrystalline cellulose with a mean particle size of 50 μ m or 100 μ m compared to 180 μ m is used in the levothyroxine sodium formulation.

(C) **Stability of Levothyroxine Sodium Tablets:** effect of water content.

40 The data shows that a higher levothyroxine sodium content is maintained in tablets after 3 months storage where the initial water content of the tablets is 4.1 or 4.7% compared to 2.4 or 2.7%.

(A) **Stability of Levothyroxine Sodium Tablets:** comparison of levothyroxine sodium tablets prepared according to Example 1(b) with Eltroxin™ tablets.

Levothyroxine sodium tablets	Tablets strength [µg]	Storage conditions	Levothyroxine Sodium contents [%]*					Total impurities contents [%]				
			Storage time [months]				Storage time [months]					
			Initial value	3	6	9	12	Initial value	3	6	9	12
Example 1 (b)	100	40°C/75%RH 30°C/60%RH 25°C/60%RH	101.0	94.3	90.5	-	-	1.2	3.5	4.8	-	-
				100.2	98.2	96.1	94.3		1.7	2.8	3.3	3.8
				101.6	100.6	100.7	97.7		1.2	1.8	2.6	2.6
Example 1 (b)	50	40°C/75%RH 30°C/60%RH 25°C/60%RH	101.4	92.0	84.4	-	-	1.1	3.8	6.1	-	-
				100.0	99.6	98.6	93.8		2.7	2.9	3.4	3.8
				99.8	102.4	101.4	98.2		2.1	2.5	2.7	3.2
Eltroxin™	100	40°C/75%RH 30°C/60%RH 25°C/60%RH	98.0	89.5	83.4	-	-	1.2	7.5	8.9	-	-
				93.4	88.2	89.5	-		4.9	7.0	6.6	-
				95.7	92.7	92.1	-		4.5	4.8	5.4	-

* % to declaration

5 ' - ' not tested

(B) **Stability of Levothyroxine Sodium Tablets:** effect of microcrystalline cellulose particle size on levothyroxine sodium tablets prepared according to Example 1(b)

Microcrystalline cellulose grade	Mean particle size [μm]	Storage conditions : 40°C/75%RH					
		Levothyroxine Sodium contents [%]*			Total impurities contents [%]		
		Time [weeks]			Time [weeks]		
		2	8	12	2	8	12
101	50	99.7	98.1	98.3	0.0	2.6	2.8
		99.6	95.6	95.4	0.6	2.3	1.6
102	100	95.8	90.2	88.6	4.8	6.1	6.6
		96.0	90.5	86.8	2.3	5.0	5.5
200	180	91.6	87.5	80.9	2.1	7.7	-

* % to initial value (initial value equals 100%)

5

10

15

(C) **Stability of Levothyroxine Sodium Tablets:** effect of water content on levothyroxine sodium tablets prepared according to Example 1(b)

Tablets strength [µg]	Storage conditions	Loss of drying [%]		Levothyroxine Sodium contents [%]*	
		Storage time [months]		Storage time [months]	
		Initial value	3	Initial value	3
100	40°C/75%RH	4.1	5.1	100.6	91.6
	30°C/60%RH		5.1		97.3
	25°C/60%RH		4.4		99.5
100	40°C/75%RH	2.7	2.8	99.7	83.0
	30°C/60%RH		2.6		94.3
	25°C/60%RH		2.7		94.5
50	40°C/75%RH	4.7	5.7	101.4	92.0
	30°C/60%RH		5.1		100.0
	25°C/60%RH		4.9		99.8
50	40°C/75%RH	2.4	1.6	100.6	82.0
	30°C/60%RH		1.4		90.1
	25°C/60%RH		1.2		91.6

Example 3: Disintegration of Levothyroxine Sodium Tablets

The disintegration of Levothyroxine Sodium tablets prepared according to Example 1(b) was tested according to the British Pharmacopeia (BP) 2002 (General Monograph for

5 Tablets, Uncoated Tablets, Disintegration Test).

The results are presented in table (D):

(D) Disintegration of Levothyroxine Sodium Tablets

Tablets strength [µg]	Storage conditions	Disintegration time [min, s]				
		Initial value	3	6	9	12
100	40°C/75%RH	0mins 38secs	2mins 14secs	2mins 00secs	-	-
	30°C/60%RH		0mins 37secs	2mins 52secs	1mins 26secs	0mins 57secs
	25°C/60%RH		0mins 36secs	1mins 00secs	1mins 38secs	0mins 53secs
50	40°C/75%RH	0mins 31secs	1mins 40secs	1mins 56secs	-	-
	30°C/60%RH		0mins 33secs	0mins 32secs	0mins 59secs	1mins 49secs
	25°C/60%RH		0mins 29secs	0mins 46secs	0mins 45secs	0mins 53secs

10 ' - ' not tested

Conclusion**(D) Disintegration of Levothyroxine Sodium Tablets**

15

The data shows that disintegration of tablets prepared according to Example 1(b) is very fast (less than 4 minutes). The pharmacopoeia for uncoated tablets requires disintegration time only less than 15 minutes.

20

Throughout the specification and the claims which follow, unless the context requires otherwise, the word "comprise" and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers but not to the exclusion of any other integer or step or group of integers or steps.

- 11A -

The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which
5 this specification relates.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A pharmaceutical formulation comprising: (a) an effective amount of levothyroxine sodium, (b) microcrystalline cellulose which has a mean particle size of less than 125 μ m and is present in an amount of 60 to 85% w/w based upon the total weight of the formulation, and (c) pregelatinised starch present in an amount of 5 to 30% w/w based upon total weight of the formulation.
2. A pharmaceutical formulation as claimed in claim 1 wherein the microcrystalline cellulose has a mean particle size less than or equal to 100 μ m.
3. A pharmaceutical formulation as claimed in claim 1 or claim 2 wherein the ratio of microcrystalline cellulose:pregelatinised starch is in the range of 2:1 to 15:1.
4. A pharmaceutical composition as claimed in any one of claims 1-3 wherein the microcrystalline cellulose and pregelatinised starch comprise water which is present in an amount 3-6% w/w based on the total weight of the formulation.
5. A pharmaceutical formulation as claimed in any one of claims 1-4 wherein the levothyroxine sodium is hydrated.
6. A pharmaceutical formulation as claimed in claim 5 wherein the levothyroxine sodium is the pentahydrate form.
7. A pharmaceutical formulation as claimed in any one of claims 1-6 which further comprises one or more glidant/lubricants.
8. A pharmaceutical formulation as claimed in claim 7 wherein the glidant/lubricants are selected from: colloidal anhydrous silica, talc and/or magnesium stearate.
9. A pharmaceutical formulation as claimed in any one of claims 1-8 which is stable to the extent that potency decreases by less than 5% when the pharmaceutical formulation is stored at 25°C and 60% relative humidity for 12 months.
10. A pharmaceutical formulation as claimed in any one of claims 1-9 in unit dose form.
11. A pharmaceutical formulation as claimed in claim 10 wherein the unit dose form is a tablet.
12. A pharmaceutical formulation as claimed in any one of claims 1-11 for use in medical therapy.

- 13 -

13. A pharmaceutical formulation as claimed in any one of claims 1-11 for use in the treatment of thyroid hormone disorders in a mammal, such as man.
14. Use of a pharmaceutical formulation as claimed in any one of claims 1-11 in the manufacture of a medicament for the treatment of thyroid hormone disorders in a mammal such as man.
15. A method of treating thyroid hormone disorders comprising administering a pharmaceutical formulation as claimed in any one of claims 1-11.
16. A process for preparing a pharmaceutical formulation as claimed in any one of claims 1-11 comprising (a) preparing a triturate of levothyroxine sodium, (b) mixing the triturate with the remaining components of the pharmaceutical formulation, and (c) compression.
17. A pharmaceutical formulation of claim 1, a use of claim 14, a method of claim 15 or a process of claim 16, substantially as hereinbefore described and/or exemplified.